• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.嵌合抗原受体共刺激结构域调节人调节性 T 细胞功能。
JCI Insight. 2019 Mar 14;5(8):126194. doi: 10.1172/jci.insight.126194.
2
Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.嵌合抗原受体 (CAR) Treg:诱导免疫耐受的一种有前途的方法。
Front Immunol. 2018 Oct 12;9:2359. doi: 10.3389/fimmu.2018.02359. eCollection 2018.
3
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
4
Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.调节性 T 细胞整合天然和 CAR 介导的共刺激信号,以控制移植物排斥反应。
JCI Insight. 2023 Oct 9;8(19):e167215. doi: 10.1172/jci.insight.167215.
5
Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.表达 MHC 特异性嵌合抗原受体的人 CD8+ Tregs 可增强对 NSG 小鼠的人皮肤排斥和移植物抗宿主病的抑制作用。
Blood Adv. 2019 Nov 26;3(22):3522-3538. doi: 10.1182/bloodadvances.2019000411.
6
Human OX40L-CAR-T target activated antigen-presenting cells and control T cell alloreactivity.人 OX40L-CAR-T 靶向激活抗原呈递细胞和控制 T 细胞同种异体反应。
Sci Transl Med. 2024 Oct 16;16(769):eadj9331. doi: 10.1126/scitranslmed.adj9331.
7
CD4 T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice.经 FVIII-CAR 和鼠 Foxp3 工程化的 CD4 T 细胞可抑制血友病 A 小鼠的抗 FVIII 免疫反应。
Cell Immunol. 2020 Dec;358:104216. doi: 10.1016/j.cellimm.2020.104216. Epub 2020 Sep 16.
8
Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?调控免疫细胞:引入抗原特异性调节 T 细胞治疗自身免疫疾病的下一步?
Cell Immunol. 2020 Dec;358:104236. doi: 10.1016/j.cellimm.2020.104236. Epub 2020 Oct 13.
9
Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.针对供体HLA I类的嵌合抗原受体的表达增强了人类调节性T细胞预防人类皮肤移植排斥反应的能力。
Am J Transplant. 2017 Apr;17(4):931-943. doi: 10.1111/ajt.14185. Epub 2017 Feb 1.
10
Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.新型胰岛素特异性嵌合抗原受体修饰的调节性 T 细胞有望成为 1 型糖尿病的免疫治疗候选药物。
J Autoimmun. 2019 Sep;103:102289. doi: 10.1016/j.jaut.2019.05.017. Epub 2019 Jun 5.

引用本文的文献

1
HLA-A2 CAR/IL-2-CISC engineered Treg display robust and antigen-specific regulatory function.HLA - A2嵌合抗原受体/白细胞介素 - 2 - 顺式作用免疫刺激复合体工程化调节性T细胞表现出强大的抗原特异性调节功能。
Mol Ther Methods Clin Dev. 2025 Aug 14;33(3):101561. doi: 10.1016/j.omtm.2025.101561. eCollection 2025 Sep 11.
2
Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells.通过嵌合抗原受体调节性T细胞革新异基因移植物耐受性
Biomedicines. 2025 Jul 18;13(7):1757. doi: 10.3390/biomedicines13071757.
3
ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche.ST2/IL-33轴阻断抑制白血病龛中调节性T细胞对CD8 T细胞的细胞毒性。
Nat Commun. 2025 Jul 21;16(1):6580. doi: 10.1038/s41467-025-61647-8.
4
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond.从天然受体到合成受体的转变:拓展T细胞工程及其他领域
Cell Mol Immunol. 2025 Jun 6. doi: 10.1038/s41423-025-01304-8.
5
Dysregulation and therapeutic prospects of regulatory T cells in type 1 diabetes.1型糖尿病中调节性T细胞的失调与治疗前景
Acta Diabetol. 2025 Mar 21. doi: 10.1007/s00592-025-02478-3.
6
T-regulatory cells for the treatment of autoimmune diseases.用于治疗自身免疫性疾病的调节性T细胞。
Front Immunol. 2025 Feb 4;16:1511671. doi: 10.3389/fimmu.2025.1511671. eCollection 2025.
7
High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.高亲和力嵌合抗原受体信号传导在人类调节性T细胞中诱导炎症程序。
Mol Ther Methods Clin Dev. 2024 Nov 18;32(4):101385. doi: 10.1016/j.omtm.2024.101385. eCollection 2024 Dec 12.
8
Harnessing the biology of regulatory T cells to treat disease.利用调节性T细胞的生物学特性治疗疾病。
Nat Rev Drug Discov. 2025 Feb;24(2):93-111. doi: 10.1038/s41573-024-01089-x. Epub 2024 Dec 16.
9
Breaking barriers: advancing cellular therapies in autoimmune disease management.突破障碍:推进自身免疫性疾病管理中的细胞疗法。
Front Immunol. 2024 Nov 29;15:1503099. doi: 10.3389/fimmu.2024.1503099. eCollection 2024.
10
Chimeric antigen receptor T-cell therapy in autoimmune diseases.嵌合抗原受体T细胞疗法在自身免疫性疾病中的应用
Front Immunol. 2024 Nov 19;15:1492552. doi: 10.3389/fimmu.2024.1492552. eCollection 2024.

本文引用的文献

1
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.抗 CD37 嵌合抗原受体 T 细胞对 B 细胞和 T 细胞淋巴瘤有效。
Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8.
2
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
3
Regulatory T cells in autoimmune disease.自身免疫性疾病中的调节性 T 细胞。
Nat Immunol. 2018 Jul;19(7):665-673. doi: 10.1038/s41590-018-0120-4. Epub 2018 Jun 20.
4
A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants.一项在活体供肾移植中使用体外扩增的受者调节性 T 细胞的 I 期临床试验。
Sci Rep. 2018 May 9;8(1):7428. doi: 10.1038/s41598-018-25574-7.
5
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
6
CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from Expansion Cultures.CD137+CD154 表达作为调节性 T 细胞(Treg)的特异性激活标志物,用于从扩增培养物中鉴定和分选稳定的人 Tregs。
Front Immunol. 2018 Feb 7;9:199. doi: 10.3389/fimmu.2018.00199. eCollection 2018.
7
Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells.比较转录组分析揭示了与肿瘤内调节性 T 细胞中 Helios 表达相关的独特遗传模块。
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2162-2167. doi: 10.1073/pnas.1720447115. Epub 2018 Feb 9.
8
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance.T 细胞受体(TCR)结合会负向影响 CD8+ 但不影响 CD4+ CAR-T 细胞的扩增和白血病的清除。
Sci Transl Med. 2017 Nov 22;9(417). doi: 10.1126/scitranslmed.aag1209.
9
Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.工程化耐受性:调节性T细胞的定制发育、功能及抗原特异性
Front Immunol. 2017 Nov 3;8:1460. doi: 10.3389/fimmu.2017.01460. eCollection 2017.
10
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.嵌合抗原受体中 4-1BB 共刺激会阻碍 T 细胞存活,且具有载体依赖性。
Cell Rep. 2017 Oct 3;21(1):17-26. doi: 10.1016/j.celrep.2017.09.015.

嵌合抗原受体共刺激结构域调节人调节性 T 细胞功能。

Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.

机构信息

Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA.

Harvard Immunology Program, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

JCI Insight. 2019 Mar 14;5(8):126194. doi: 10.1172/jci.insight.126194.

DOI:10.1172/jci.insight.126194
PMID:30869654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6538349/
Abstract

Regulatory T cells (Tregs) are key modulators of inflammation and are important for the maintenance of peripheral tolerance. Adoptive immunotherapy with polyclonal Tregs holds promise in organ transplantation, graft-versus-host disease, and autoimmune diseases, but may be enhanced by antigen-specific, long-lived Treg cells. We modified primary human Tregs with chimeric antigen-receptors (CARs) bearing different costimulatory domains and performed in vitro analyses of their phenotype and function. While neither the presence of a CAR nor the type of costimulation domain influenced Foxp3 expression in Tregs, the costimulation domain of the CARs affected CAR Treg surface phenotype and functions such as cytokine production. Furthermore, signaling from the CD28 costimulation domain maintained CAR Treg suppressor function, whereas 4-1B costimulation did not. In vivo, CAR Tregs accumulated at sites expressing target antigen, and suppressed antigen specific effector T cell responses; however, only CAR Tregs with CD28 signaling domains were potent inhibitors of effector T cell mediated graft rejection in vivo. Our findings support the use of CD28 based CAR-Tregs for tissue specific immune suppression in the clinic.

摘要

调节性 T 细胞(Tregs)是炎症的关键调节剂,对于维持外周耐受非常重要。过继性免疫治疗中使用多克隆 Tregs 有望应用于器官移植、移植物抗宿主病和自身免疫性疾病,但抗原特异性、长寿命的 Treg 细胞可能会增强其疗效。我们使用嵌合抗原受体(CAR)对原代人 Tregs 进行修饰,这些 CAR 带有不同的共刺激结构域,并对其表型和功能进行了体外分析。虽然 CAR 的存在或共刺激结构域的类型都不会影响 Treg 中的 Foxp3 表达,但 CAR 上的共刺激结构域会影响 CAR-Treg 的表面表型和功能,如细胞因子的产生。此外,CD28 共刺激域的信号传导维持了 CAR-Treg 的抑制功能,而 4-1BB 共刺激则没有。在体内,CAR-Tregs 会在表达靶抗原的部位聚集,并抑制抗原特异性效应 T 细胞的反应;然而,只有带有 CD28 信号域的 CAR-Tregs 才能在体内有效抑制效应 T 细胞介导的移植物排斥反应。我们的研究结果支持在临床上使用基于 CD28 的 CAR-Tregs 进行组织特异性免疫抑制。